The Levels of Serum Biomarkers in Stable Asthma Patients with Comorbidities
The effects of comorbidities on systemic inflammation markers in stable asthmatics and the consequences of such effects have not been well evaluated. We aimed to evaluate the effect of comorbidities on clinical manifestations and systemic inflammation in asthmatic patients under control. The study group consisted of asthmatic patients who applied to our pulmonology outpatient clinic and volunteered to participate. 120 clinically stable asthma patients (71 females and 49 males) and 35 healthy controls (19 females and 16 males) with similar age, gender, and body mass index distributions were admitted to the study. The levels of osteopontin, interleukin 6 (IL-6), interleukin 8 (IL-8), interleukin 13 (IL-13), eosinophilic cationic protein, adiponectin, and high-sensitivity C-reactive protein of the individuals were evaluated using commercial ELISA kits by taking venous blood samples. Of 120 asthmatic subjects, 47 (39, 2%) had comorbidities and allergic rhinitis (15%) coexisted most frequently. Other comorbidities associated with asthma were gastroesophageal reflux, sinusitis, hypertension, diabetes, gastritis, and peptic ulcus respectively. There was no physician-diagnosed comorbidity in the control group. The levels of IL-6 and IL-8 were found higher in asthma group with comorbidities when compared to those with no comorbidities (p were 0.032 and 0.046, respectively). Comorbidities interfere with the diagnosis and treatment of asthma, besides affecting the disease control. Our findings suggest the possibility of the impact of comorbidities on systemic inflammation markers, especially IL-6 and IL-8. To evaluate the impact of comorbidities on asthma control and systemic markers, further studies are needed.
1. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire MD, Weiss KB, et al. Worldwide Severity and Control of Asthma in Children and Adults :The Global Asthma İnsights and Reality Surveys. J Allergy Clin Immunol 2004; 114: 40-47.
2. Sekerel BE, Gemicioglu B, Soriano JB. Asthma Insights and Reality in Turkey [AIRET] study. RespirMed 2006; 100: 1850-1854.
3. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org
4. Ledford DK, Lockey RF. Asthma and Comorbidities. Curr Opin Allergy Clin Immunol 2013; 13: 78-86.
5. Boulet LP. Influence of Comorbid Conditions on Asthma. Eur Respir J 2009; 33: 897-906.
6. Zhang T, Carleton BC, Prosser RJ, Smith AM. The Added Burden of Comorbidity in Patients with Asthma. J Asthma 2009; 46: 1021-1026.
7. Cazzola M, Segreti A, Calzetta L, Rogliani P. Comorbidities of asthma: current knowledge and future researchneeds. Curr Opin Pulm Med 2013; 19: 36-41.
8. Wouters EF, Reynaert NL, Dentener MA, et al. Systemic and local inflammation in asthma and chronicobstructive pulmonary disease: is there a connection? Proc Am Thorac Soc 2009; 6: 638-647.
9. Monteseirín J. Neutrophils and asthma. J Investig Allergol Clin Immunol 2009; 19: 340-354.
10. Wadsworth SJ, Sin DD, Dorscheid DR. Clinical update on the use of biomarkers of airwayinflammation in the management of asthma. J Asthma Allergy 2011; 4: 77-86.
11. Ilmarinen P, Tuomisto LE, Niemelä O, Danielsson J, Haanpää J, Kankaanranta T, et al. Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. Eur Respir J 2016; 48: 1052-1062.
12. Konno S, Kurokawa M, Uede T, Nishimura M, Huang SK. Role of osteopontin, a multifunctional protein, in allergy and asthma. Clin Exp Allergy 2011; 41: 1360-1366.
13. Sood A, Shore SA. Adiponectin, Leptin, and Resistin in Asthma: Basic Mechanisms through Population Studies. J Allergy [Cairo] 2013; 2013: 785835. doi: 10.1155/2013/785835.
14. Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J 2011;38(1): 42-49.
15. Park J, Kim TB, Joo H, Lee JS, Lee SD, Oh YM. Diseases concomitant with asthma in middle-aged and elderlysubjects in Korea: A population-based study. Allergy Asthma Immunol Res 2013;5(1):16-25.
16. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur Respir J 2008; 31: 320-325.
17. Pérez De Llano LA, González FC, Añón OC, Perea MP, Caruncho MV, Villar AB. Relationship Between Comorbidity and Asthma Control. Arch Bronconeumol 2010; 46 (10): 508-513.
18. Su X, Ren Y, Li M , Zhao X, Kong L, Kang J. Prevalence of Comorbidities in Asthma and Nonasthma Patients: A Meta-analysis. Medicine [Baltimore]. 2016; 95 (22): e3459.
19. Thomas M, Price D. Impact of Comorbidities on Asthma. Expert Rev Clin Immunol 2008; 4: 731-742.
20. Brinke A, Sterk PJ, Masclee AA, Spinhoven P, Schmidt JT, Zwinderman AH. Risk Factors of Frequent Exacerbations in Difficult-to-Treat Asthma. Eur Respir J 2007; 26(5): 812–818.
21. Olafsdottir IS, Gislason T, Thjodleifsson B, Olafsson I, Gislason D, Jögi R, et al. C Reactive Protein Levels are Increased in Non-Allergic but Not Allergic Asthma: a Multicentre Epidemiologic Study. Thorax 2005;60:451-454.
22. Ali Hasan H, İbrahim AI. Risk Factors That are Associated with Interleukin-8 Level in Iraqı Asthmatic Patients. Asian J Pharm Clin Res 2013; 6: 242-245.
23. Zhao JJ, Yang L, Zhao FQ, Shi SM, Tan P. Osteopontin Levels are Elevated in Patients with Asthma. J Int MedRes 2011; 39: 1402-1407.
24. Liu W, Xia W, Fan Y, Wang H, Zuo K, Lai Y, et al. Elevated Serum Osteopontin Level is Associated With Blood Eosinophilia and Asthma Comorbidity in Patients with Allergic Rhinitis. J Allergy Clin Immunol 2012; 130: 1416-1418.
25. Sood A, Dominic E, Qualls C, Steffes MW, Thyagarajan B, Smith LJ, et al. Serum Adiponectin is Associated with Adverse Outcomes of Asthmain Men But Not in Women. Front Pharmacol 2011; 2: 55. doi: 10.3389/fphar.2011.00055.